| Literature DB >> 28286556 |
Junichi Sato1, Masanao Nakamura2, Osamu Watanabe1, Takeshi Yamamura3, Kohei Funasaka1, Eizaburo Ohno1, Ryoji Miyahara1, Hiroki Kawashima1, Hidemi Goto1, Yoshiki Hirooka3.
Abstract
BACKGROUND: Colon capsule endoscopy (CCE) is a procedure in which capsule swallowing facilitates observation of the lumen of the entire digestive tract. It does not require an air supply, and is a noninvasive procedure with a markedly low risk of adverse events in comparison with conventional colonoscopy (CS). It reduces patient stress, and may be acceptable to patients. A limitation of this procedure is that the entire colon observation rate (CCE excretion rate, completed CCE rate) is not 100%. In this study, we prospectively investigated clinical factors important to achieve observation of the entire colon on CCE.Entities:
Keywords: body mass index; capsule endoscopy; colon; constipation; gastrointestinal endoscopy; water intake
Year: 2016 PMID: 28286556 PMCID: PMC5330613 DOI: 10.1177/1756283X16673556
Source DB: PubMed Journal: Therap Adv Gastroenterol ISSN: 1756-283X Impact factor: 4.409
Schedule of bowel preparation used in the study.
| Schedule | Intake |
|---|---|
| Day 2, before bedtime | 2 Senna tablets, 12 mg each |
| Day 1, all day | 3 meals: low-fiber diet, sugar supplementation if necessary |
| 20:00 | Magnesium citrate 50 g (180 ml): hypertonic method |
| Before bedtime | 2 Senna tablets |
| Day of examination | |
| 08:30 | 1.5 l PEG |
| 10:00 | Capsule ingestion with mosapride citrate 20 mg. Attachment of a pedometer |
| 11:00 | Real-time monitoring |
| • If CCE remains in the stomach, additional examination should be conducted after 1 h. If it still remains in the stomach at that point, metoclopramide 10 mg should be intramuscularly injected. | |
| • If it is present in the small intestine, the 1st booster should be started. | |
| 1st boost (within 2 h) | Each patient drinks a mixture of PEG 1000 ml and water 1000 ml. Candies and gum are permitted. |
| • Real-time monitoring | |
| The right colon or lumen seems to be dilated. | |
| If the left colon or wall is reached, left abdominal compression (5 s × 5 sets)/using stairs/walking/postural changes/exercise to strengthen the abdominal muscles* should be conducted. | |
| →2nd boost | |
| 2nd boost | Sodium picosulfate 48 mg |
| • Real-time monitoring (30 min after the completion of the 2nd boost) | |
| The * items should be performed. →3rd boost | |
| 3rd boost | Magnesium citrate 50 g (900 ml): isotonic method |
| If necessary, The * items should be performed. | |
| • Subsequently, additional drinks, light meals, irritating suppositories, enema, or the muscular injection of metoclopramide 10 mg should be decided after consultation with each patient. |
CCE, colon capsule endoscope; PEG, polyethylene glycol.
Patient characteristics.
| Number of patients | 64 |
| Mean age (years) | 57.8 (25–87) |
| Male/female | 36/28 |
| BMI (%) | 22.7 (16.2–31.6) |
| Constipation (%) | 16 (25.0) |
| Previous abdominal surgery (%) | 23 (35.9) |
| Abdominal symptoms (%) | 26 (40.6) |
| Diabetes (%) | 8 (12.5) |
| Ulcerative colitis (%) | 10 (15.6) |
| Charlson comorbidity index | 0.66 (0–4) |
BMI, body mass index.
Results of CCE procedure.
| Number of excreted CCE (%) | 52 (81.3) |
| Gastric transit time (min) | 44.6 (1–205) |
| Small intestinal transit time (min) | 61.0 (6–177) |
| Colorectal transit time (min) | 134.7 (3–529) |
| Duration of examination (min) | 355.5 (75–999) |
| Colon cleansing level | |
| Adequate (%) | |
| Right colon | 95.9 |
| Transverse colon | 98.0 |
| Left colon | 95.9 |
| Rectum | 89.8 |
| Proportion of patients with findings (%) | 95.3 |
| Primary findings (%) | |
| Diverticulum | 62.5 |
| Colorectal polyp | 50.0 |
| Erosion/flare | 35.9 |
| Hemorrhoid | 21.9 |
| Ulcerative colitis | 15.6 |
| Adverse events (%) | 0 |
| Final site of CCE arrival in the nonexcretion group (%) | |
| Left colon | 91.7 |
| Right colon | 8.3 |
| Total water intake (ml) | 3895.8 (2000–7700) |
CCE, colon capsule endoscope.
Comparison of excretion and nonexcretion group.
| Excretion group | Nonexcretion group | ||
|---|---|---|---|
| Number of patients | 52 | 12 | |
| Mean age (years) | 56.2 (25–84) | 64.7 (39–87) | |
| Male/female | 32/20 | 4/8 | |
| BMI | 22.8 (16.2–31.6) | 22.1 (17.2–27.3) | |
| Constipation (%) | 9 (17.3) | 6 (50.0) | |
| Previous abdominal surgery (%) | 17 (32.7) | 6 (50.0) | |
| Abdominal symptoms (%) | 18 (34.6) | 8 (66.7) | |
| Diabetes (%) | 4 (7.7) | 4 (33.3) | |
| Ulcerative colitis (%) | 9 (17.3) | 1 (8.3) | |
| Charlson comorbidity index | 0.60 (0–4) | 0.92 (0–2) | |
| Number of steps during examination (steps/min) | 9.46 (2.57–25.24) | 6.63 (0.071–17.4) | |
| Water intake during examination (ml/min) | 13.6 (3.94–43.8) | 6.45 (3.11–13.8) | |
| Gastric transit time (min) | 44.4 (5–205) | 45.6 (1–94) | |
| Small intestinal transit time (min) | 60.4 (6–177) | 63.6 (21–132) | |
| Diverticulum | 31 (59.6) | 9 (75.0) | |
| Colorectal polyp | 26 (50.0) | 6 (50.0) |
Mann–Whitney test **Fisher’s exact method.
BMI, Body mass index.
Logistic analysis of factors influencing complete CCE.
| Number of patients | Excreted (%) | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|---|
| P-value | Odds ratio (95% confidence interval) | P-value | Odds ratio (95% confidence interval) | |||
| Age | 0.081 | |||||
| ⩾65 | 23 | 16 (69.6) | 0.317 (0.087–1.153) | 0.158 | 0.151 (0.011–2.086) | |
| <65 | 41 | 36 (87.8) | 1.000 | |||
| Sex | 0.085 | |||||
| Male | 36 | 32 (88.9) | 3.200 | 0.445 | 2.346 (0.263–20.884) | |
| Female | 28 | 20 (71.4) | 1.000 | |||
| BMI | 0.838 | |||||
| 25⩽ | 12 | 10 (83.3) | 1.190 (0.225–6.308) | 0.409 | 5.937 | |
| <25 | 52 | 42 (80.8) | 1.000 | |||
| Constipation | 0.022 | |||||
| Yes | 15 | 9 (60.0) | 1.000 | 0.898 | 1.197 (0.076–18.779) | |
| No | 49 | 43 (87.8) | 4.778 | |||
| Previous abdominal surgery | 0.266 | |||||
| Yes | 23 | 17 (73.9) | 0.486 (0.136–1.732) | 0.526 | 0.461 (0.042–5.027) | |
| No | 41 | 35 (85.4) | 1.000 | |||
| Abdominal symptoms | 0.050 | |||||
| Yes | 26 | 18 (69.2) | 1.000 | 0.197 | 4.220 (0.473–37.657) | |
| No | 38 | 34 (89.5) | 3.778 | |||
| Diabetes | 0.026 | |||||
| Yes | 8 | 4 (50.0) | 1.000 | 0.149 | 30.015 | |
| No | 56 | 48 (85.7) | 6.000 | |||
| Ulcerative colitis | 0.451 | |||||
| Yes | 10 | 9 (90.0) | 2.302 | 0.864 | 0.750 (0.028–20.270) | |
| No | 54 | 43 (79.6) | 1.000 | |||
| Charlson’s comorbidity index | 0.266 | |||||
| ⩾1 | 23 | 17 (73.9) | 0.486 (0.136–1.732) | 0.204 | 9.751 | |
| 0 | 41 | 35 (85.4) | 1.000 | |||
| Number of steps during examination (steps/min) | 0.034 | |||||
| ⩾5.0 | 48 | 42 (87.5) | 4.200 | 0.313 | 5.933 | |
| <5.0 | 16 | 10 (62.5) | 1.000 | |||
| Water intake during examination (mL/min) | 0.015 | |||||
| ⩾12.0 | 30 | 29 (96.7) | 13.870 | 0.025 | 46.753 | |
| <12.0 | 34 | 23 (67.6) | 1.000 | |||
| Gastric transit time (min) | 0.201 | |||||
| ⩾30 | 21 | 19 (90.5) | 2.879 | 0.326 | 3.984 (0.253–62.676) | |
| <30 | 43 | 33 (76.7) | 1.000 | |||
| Small intestinal transit time (min) | 0.718 | |||||
| ⩾60 | 29 | 23 (79.3) | 1.000 | 0.255 | 0.277 (0.030–2.527) | |
| <60 | 35 | 29 (82.9) | 1.261 (0.359–4.432) | |||
| Diverticulum | 0.327 | |||||
| Yes | 40 | 31 (77.5) | 0.492 (0.119–2.034) | 0.438 | 2.640 (0.227–30.638) | |
| No | 24 | 21 (87.5) | 1.000 | |||
| Colorectal polyp | 1.000 | |||||
| Yes | 32 | 26 (81.3) | 1.000 (0.285–3.509) | 0.793 | 1.307 (0.177–9.627) | |
| No | 32 | 26 (81.3) | 1.000 | |||
Logistic analysis of factors influencing complete CCE within 4 hours.
| Number of patients | Achieved (%) | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|---|
| P-value | Odds ratio (95% confidence interval) | P-value | Odds ratio (95% confidence interval) | |||
| Age | 0.942 | |||||
| ⩾65 | 23 | 11 (47.8) | 0.963 (0.346–2.674) | 0.168 | 3.826 (0.567–25.807) | |
| <65 | 41 | 20 (48.8) | 1.000 | |||
| Sex | 0.198 | |||||
| Male | 36 | 20 (55.6) | 1.932 (0.708–5.271) | 0.538 | 0.564 (0.091–3.497) | |
| Female | 28 | 11 (39.3) | 1.000 | |||
| BMI | 0.169 | |||||
| 25⩽ | 12 | 8 (66.7) | 2.522 (0.674–9.431) | 0.039 | 13.723 (1.135–165.913) | |
| <25 | 52 | 23 (44.2) | 1.000 | |||
| Constipation | 0.018 | |||||
| Yes | 15 | 3 (20.0) | 1.000 | 0.030 | 13.988 | |
| No | 49 | 28 (57.1) | 5.333 (1.334–21.325) | |||
| Previous abdominal surgery | 0.942 | |||||
| Yes | 23 | 11 (47.8) | 0.963 (0.346–2.674) | 0.918 | 0.904 (0.132–6.199) | |
| No | 41 | 20 (48.8) | 1.000 | |||
| Abdominal symptoms | 0.762 | |||||
| Yes | 26 | 12 (46.2) | 1.000 | 0.684 | 0.714 (0.141–3.608) | |
| No | 38 | 19 (50.0) | 1.167 (0.429–3.170) | |||
| Diabetes | 0.173 | |||||
| Yes | 8 | 2 (25.0) | 1.000 | 0.256 | 4.500 (0.335–60.406) | |
| No | 56 | 29 (51.8) | 3.222 (0.598–17.358) | |||
| Ulcerative colitis | 0.044 | |||||
| Yes | 10 | 8 (80.0) | 5.391 (1.045–27.812) | 0.065 | 18.129 | |
| No | 54 | 23 (42.6) | 1.000 | |||
| Charlson’s comorbidity index | 0.942 | |||||
| ⩾1 | 23 | 11 (47.8) | 0.963 (0.346–2.674) | 0.981 | 1.023 (0.155–6.737) | |
| 0 | 41 | 20 (48.8) | 1.000 | |||
| Number of steps during examination (steps/min) | 0.665 | |||||
| ⩾5.0 | 48 | 24 (50.0) | 1.286 (0.412-4.013) | 0.427 | 0.414 (0.047-3.655) | |
| <5.0 | 16 | 7 (43.8) | 1.000 | |||
| Water intake during examination (mL/min) | >0.001 | |||||
| ⩾12.0 | 30 | 23 (76.7) | 10.679 (3.350-34.036) | 0.004 | 12.028 (2.225-65.029) | |
| <12.0 | 34 | 8 (23.5) | 1.000 | |||
| Gastric transit time (min) | 0.332 | |||||
| ⩾30 | 21 | 12 (57.1) | 1.684 (0.587-4.828) | 0.629 | 1.515 (0.282-8.141) | |
| <30 | 43 | 19 (44.2) | 1.000 | |||
| Small intestinal transit time (min) | 0.045 | |||||
| ⩾60 | 29 | 10 (34.5) | 1.000 | 0.590 | 1.603 (0.288-8.940) | |
| <60 | 35 | 21 (60.0) | 2.850 (1.026-7.916) | |||
| Diverticulum | 0.084 | |||||
| Yes | 40 | 16 (40.0) | 0.400 (0.141-1.132) | 0.656 | 0.665 (0.111-3.990) | |
| No | 24 | 15 (62.5) | 1.000 | |||
| Colorectal polyp | 0.803 | |||||
| Yes | 32 | 16 (50.0) | 1.133 (0.425-3.023) | 0.731 | 1.307 (0.284-6.005) | |
| No | 32 | 15 (46.9) | 1.000 | |||